UCLA Researchers Develop Method to Address Fuel Shortages in Cancer Immunotherapy

A new preclinical study conducted by a team at UCLA has uncovered a method to deliver needed glucose to immune cells in a way that tumor cells cannot hijack. Many immunotherapies developed to combat cancer fail because the CAR-T cells become exhausted after being starved of oxygen in the tumor environment. This offers hope of keeping anti-cancer fighter cells active and deadly to both solid and non-solid tumors. This method of tweaking the metabolic pathways delivering energy to fighter immune cells could provide valuable insights to enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are currently developing immunotherapies.

The research addresses a fundamental challenge in the field of cancer immunotherapy, where the very environment tumors create to survive becomes a barrier to treatment success. Tumor microenvironments are often hypoxic, meaning they have low oxygen levels, and they aggressively consume available nutrients like glucose. This metabolic competition starves the engineered CAR-T cells that are introduced to attack the cancer, leading to their exhaustion and functional failure. The UCLA team's approach focuses on modifying how these therapeutic cells access and utilize energy, essentially providing them with a metabolic advantage over the cancer cells they are meant to destroy.

By preventing tumor cells from hijacking the glucose supply, the method aims to sustain the potency and longevity of CAR-T cells within tumors. This is particularly significant for treating solid tumors, which have historically been more resistant to CAR-T therapy compared to blood cancers. The ability to keep these immune cells "fueled" and active could translate to more durable responses and improved patient outcomes. The implications extend beyond a single research project, potentially influencing the strategic direction of numerous biotechnology companies engaged in similar therapeutic development.

For more information on specialized communications in the biomedical sector, please visit https://www.BioMedWire.com. The full terms of use and disclaimers applicable to all content are available at https://www.BioMedWire.com/Disclaimer. The development represents a targeted intervention in cellular metabolism that could unlock the broader potential of immunotherapies, moving them closer to becoming reliable treatments for a wider array of cancers.